JP5498936B2 - Ｓｍｏアンタゴニストであるトリアゾール誘導体 - Google Patents

Ｓｍｏアンタゴニストであるトリアゾール誘導体 Download PDF

Info

Publication number
JP5498936B2
JP5498936B2 JP2010504069A JP2010504069A JP5498936B2 JP 5498936 B2 JP5498936 B2 JP 5498936B2 JP 2010504069 A JP2010504069 A JP 2010504069A JP 2010504069 A JP2010504069 A JP 2010504069A JP 5498936 B2 JP5498936 B2 JP 5498936B2
Authority
JP
Japan
Prior art keywords
methyl
compound
bicyclo
triazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010504069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524937A5 (enExample
JP2010524937A (ja
Inventor
バルコベック，ジェームス，エム
ティエリンガー，ロルフ
ワデル，シャーマン，ティー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2010524937A publication Critical patent/JP2010524937A/ja
Publication of JP2010524937A5 publication Critical patent/JP2010524937A5/ja
Application granted granted Critical
Publication of JP5498936B2 publication Critical patent/JP5498936B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010504069A 2007-04-18 2008-04-15 Ｓｍｏアンタゴニストであるトリアゾール誘導体 Active JP5498936B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92501807P 2007-04-18 2007-04-18
US60/925,018 2007-04-18
PCT/US2008/004862 WO2008130552A1 (en) 2007-04-18 2008-04-15 Triazole derivatives which are smo antagonists

Publications (3)

Publication Number Publication Date
JP2010524937A JP2010524937A (ja) 2010-07-22
JP2010524937A5 JP2010524937A5 (enExample) 2011-05-19
JP5498936B2 true JP5498936B2 (ja) 2014-05-21

Family

ID=39433852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504069A Active JP5498936B2 (ja) 2007-04-18 2008-04-15 Ｓｍｏアンタゴニストであるトリアゾール誘導体

Country Status (12)

Country Link
US (1) US7691887B2 (enExample)
EP (1) EP2136803B1 (enExample)
JP (1) JP5498936B2 (enExample)
CN (1) CN101663033B (enExample)
AR (1) AR066063A1 (enExample)
AT (1) ATE555785T1 (enExample)
AU (1) AU2008241527B2 (enExample)
CA (1) CA2683946C (enExample)
CL (1) CL2008001074A1 (enExample)
PE (1) PE20090806A1 (enExample)
TW (1) TW200901987A (enExample)
WO (1) WO2008130552A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
CA2710377A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
EP2334683B1 (en) * 2008-08-29 2017-03-22 MSD Italia S.r.l. Saturated bicyclic heterocyclic derivatives as smo antagonists
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
AU2010321773A1 (en) * 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3，3-二氟环丁烷甲酸的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60317631T2 (de) 2002-02-01 2008-09-25 Merck & Co., Inc. 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CN1795181A (zh) 2003-05-29 2006-06-28 麦克公司 用作11β－羟基类固醇脱氢酶－1抑制剂的三唑衍生物
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2006078283A2 (en) 2004-04-30 2006-07-27 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
EP1797034B1 (en) 2004-08-06 2010-06-30 Merck Sharp & Dohme Corp. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
BRPI0514444A (pt) 2004-08-27 2008-06-10 Infinity Pharmaceuticals Inc análogos de ciclopamina e métodos de uso destes
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
CN101083996A (zh) 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
CA2587489C (en) 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
NI200800069A (es) 2005-10-20 2008-06-25 Merck & Co Inc Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1

Also Published As

Publication number Publication date
PE20090806A1 (es) 2009-06-27
CA2683946A1 (en) 2008-10-30
ATE555785T1 (de) 2012-05-15
AR066063A1 (es) 2009-07-22
AU2008241527A1 (en) 2008-10-30
US7691887B2 (en) 2010-04-06
TW200901987A (en) 2009-01-16
CN101663033A (zh) 2010-03-03
EP2136803A1 (en) 2009-12-30
AU2008241527B2 (en) 2014-02-13
CN101663033B (zh) 2013-01-16
US20080262051A1 (en) 2008-10-23
EP2136803B1 (en) 2012-05-02
CL2008001074A1 (es) 2009-06-05
JP2010524937A (ja) 2010-07-22
CA2683946C (en) 2013-01-22
WO2008130552A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
JP5498936B2 (ja) Ｓｍｏアンタゴニストであるトリアゾール誘導体
AU2020343671C1 (en) RIP1 inhibitory compounds and methods for making and using the same
US10604532B2 (en) Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases
US20110183974A1 (en) 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists
AU2017253937B2 (en) Compounds and compositions for treating conditions associated with NLRP activity
KR102083857B1 (ko) 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도
AU2014219283B2 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
TW201002683A (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
EP2334683B1 (en) Saturated bicyclic heterocyclic derivatives as smo antagonists
TW200908983A (en) Heterocyclic compounds and uses thereof
WO2010082044A1 (en) Unsaturated bicyclic heterocyclic derivatives as smo antagonists
CN108191857B (zh) 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
KR20150023880A (ko) 안드로겐 수용체 길항제로서의 ｎ-[4-(퀴놀린-4-일옥시)사이클로헥실(메틸)](헤테로)아릴카복사미드, 그의 제조, 및 의약품으로서의 그의 용도
CN109721596B (zh) 苯基取代的二氢吡啶类化合物及其用途
JP2008542242A (ja) 新規のテトラヒドロピリドチオフェン
US20130053396A1 (en) Piperidine and piperazine derivatives as smo antagonists
WO2025011008A1 (zh) 含苯基取代的二氢萘啶类化合物的药物制剂与用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110331

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120221

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130514

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140310

R150 Certificate of patent or registration of utility model

Ref document number: 5498936

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250